Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Transient Stress Cardiomyopathy


BASICS


DESCRIPTION


  • Transient stress cardiomyopathy (TSC) is a unique cause of reversible left ventricle (LV) dysfunction with a presentation indistinguishable from the acute coronary syndromes (ACS), particularly ST-segment elevation myocardial infarction (MI) (1).
  • Typically, the patient is a postmenopausal woman who presents with acute chest pain or dyspnea after an identifiable "trigger "  (i.e., an acute emotional or physiologic stressor).
  • First reported by authors from Japan, TSC was known initially as the takotsubo syndrome because the typical LV morphology (i.e., apical ballooning) resembled that of a Japanese octopus trap or takotsubo (2)[B].
  • Presenting clinical features include the following:
    • Chest symptoms and/or dyspnea
    • ECG changes, including ST-segment elevations or diffuse T-wave inversions
    • Mild elevation in cardiac biomarkers (creatine kinase [CK], troponin)
    • Transient wall motion abnormalities that may involve the base, midportion, and/or lateral walls of the LV.
    • The apex of the right ventricle (RV) may be affected in up to 25% of cases (3)[B].
  • Clinical features may vary on a case-by-case basis, and formal diagnostic criteria have not been established.
  • Authors from the Mayo Clinic have proposed that 3 of the 4 following criteria establish the diagnosis (1)[A]:
    • Transient akinesis or dyskinesis of the LV apical and midventricular segments with regional wall motion abnormalities extending beyond a single epicardial vascular distribution
    • Absence of obstructive coronary artery disease (CAD) or angiographic evidence of acute plaque rupture
    • New ECG abnormalities, either ST-segment elevation or T-wave inversion
    • Absence of
      • Recent significant head trauma
      • Intracranial bleeding
      • Pheochromocytoma
      • Obstructive epicardial CAD
      • Myocarditis
      • Hypertrophic cardiomyopathy
  • Synonym(s): takotsubo cardiomyopathy; apical ballooning syndrome; stress cardiomyopathy; broken heart syndrome; ampulla cardiomyopathy

EPIDEMIOLOGY


Incidence
  • TSC accounts for a small percentage (1 " “3%) of ACS.
  • In a recent prospective evaluation of patients admitted to the ICU, as many as 28% had apical ballooning, often in association with sepsis.
  • Predominant sex: 82 " “100% of cases occur in women.
  • Predominant age: Mean age of patients is 62 to 75 years.

Prevalence
2.2% of patients presenting to a referral hospital with ST-segment MIs were found to have TSC. ‚  

ETIOLOGY AND PATHOPHYSIOLOGY


  • The exact pathophysiology is not known.
  • A perturbation in the brain-heart axis, originating in the insular cortex, may be the inciting event (4).
  • Subsequent overwhelming activation of the sympathetic nervous system initiates a cascade of events, including the following:
    • Catecholamine-induced LV dysfunction: "biased agonism "  of epinephrine for Ž ²2-adrenergic receptors, located predominantly at the cardiac apex (5)
    • Endothelial dysfunction and vasospasm
    • Cellular metabolic injury
      • Myocardial norepinephrine release
      • Calcium overload
      • Contraction band necrosis

Genetics
No genetic associations have been described to date. ‚  

RISK FACTORS


  • Female sex
  • Postmenopausal state
  • Emotional stress (i.e., argument, death of family member)
  • Physiologic stress (i.e., acute medical illness)
  • Chronic neurologic or psychiatric disease (4)

COMMONLY ASSOCIATED CONDITIONS


Death from TSC is rare, and most cases resolve rapidly, within 2 to 3 days. Reported complications include: ‚  
  • Left-sided heart failure
  • Pulmonary edema
  • Cardiogenic shock and hemodynamic compromise
  • Dynamic LV outflow tract gradient complicated by hypotension
  • Mitral regurgitation
  • Ventricular arrhythmias
  • LV thrombus formation
  • LV free wall rupture
  • Death (rare, 0 " “8%)

DIAGNOSIS


Because TSC often is indistinguishable from an ACS, it should be treated initially as such: ‚  
  • Activate emergency medical services or report to emergency department.
  • Oxygen, IV access, and ECG monitoring
  • Urgent cardiology consultation

HISTORY


  • In ¢ … ”; of patients, there is exposure to a "trigger event. " 
    • Emotional stress: argument, death of family member, divorce, public speaking, and so forth
    • Physiologic stress: acute medical condition such as head trauma, asthma attack, seizure, and so forth
  • In ¢ … “; of patients, there is no identifiable trigger (4).
  • Acute onset of dyspnea or chest pain
  • Palpitations
  • Syncope

PHYSICAL EXAM


Exam may be unremarkable or may include any of the following: ‚  
  • Tachypnea
  • Tachycardia
  • Hypotension
  • Jugular venous distension
  • Bibasilar rales
  • S3 gallop
  • Systolic ejection murmur due to dynamic LV outflow tract gradient
  • Holosystolic murmur of mitral regurgitation

DIFFERENTIAL DIAGNOSIS


  • Acute ST-segment elevation MI
  • Pulmonary embolism
  • Myopericarditis
  • Pheochromocytoma
  • Hypertrophic cardiomyopathy
  • Subarachnoid hemorrhage or stroke

DIAGNOSTIC TESTS & INTERPRETATION


  • ECG should be done urgently and may show the following:
    • Diffuse ST-segment elevations
    • Diffuse and often dramatic T-wave inversions
    • QTc interval prolongation (6)[B]
    • Q waves
  • Laboratory tests typically reveal a mild elevation in cardiac biomarkers such as
    • CK (rarely >500 U/mL)
    • Troponin I
    • B-type natriuretic peptide (BNP)
    • Markers of high filling pressures (e.g., BNP) tend to be higher than markers of necrosis (e.g., CK, troponin).
    • TSC can be distinguished from AMI with 95% specificity using a BNP/TnT ratio ≥1,272 (sensitivity 52%) (7)[B].
  • Chest radiograph
    • Cardiomegaly
    • Pulmonary edema
  • Echocardiogram
    • Reduced LV systolic function
    • Abnormal diastolic function, including evidence of increased filling pressures
    • Regional wall motion abnormalities in one of the following patterns:
      • Classic or "takotsubo-type "  ballooning of the apex with a hypercontractile base
      • "Reverse takotsubo " : apical hypercontractility with basal akinesis
      • "Midventricular "  akinesis with apical and basal hypercontractility
      • Focal or localized akinesis of an isolated segment
    • Dynamic intracavitary LV gradient
    • Mitral regurgitation
    • Variable involvement of the RV
  • Cardiac MRI
    • Reduced LV function
    • Wall motion abnormalities as described for transthoracic echocardiography
    • Absence of delayed hyperenhancement with gadolinium

Diagnostic Procedures/Other
  • Because ST-segment elevation MI is the diagnosis of exclusion, patients typically are referred for urgent cardiac catheterization.
  • Coronary angiography
    • Nonocclusive CAD
    • Rarely, epicardial coronary spasm
    • Endothelial dysfunction as measured by fractional flow reserve or TIMI frame counts
  • Left-sided heart catheterization: increased LV end-diastolic pressure to a similar degree as AMI (8)[B]
  • Ventriculography: wall motion abnormalities as described for transthoracic echocardiography
  • Right-sided heart catheterization
    • Increased pulmonary capillary wedge pressure
    • Secondary pulmonary hypertension
    • Increased right ventricular filling pressures
    • Reduced cardiac output or cardiogenic shock (cardiac index <2 and mean arterial pressure [MAP] <60 mm Hg)

Test Interpretation
Characteristic pathologic findings of involved myocardium have not been described. ‚  

TREATMENT


  • Activation of emergency medical services
  • Advanced cardiac life support therapies as needed
  • Oxygen
  • IV access
  • ECG monitoring

MEDICATION


After diagnostic cardiac catheterization, empirical treatment goals are as follows: ‚  
  • Management of hypotension: differentiation between cardiogenic shock and dynamic LV cavity gradient
  • Management of increased filling pressures and congestive states
  • Attenuation of sympathetic drive

First Line
  • There are no evidence-based treatment recommendations for TSC.
  • Although Ž ²-blockers are of theoretical benefit, their use has not been associated with improved outcomes in observational cohorts (4)[B].
  • If there is evidence of left ventricular systolic dysfunction or pulmonary edema, consider the following:
    • Furosemide: 20 to 40 mg IV/PO BID as needed to reduce LV filling pressures and dyspnea (9)
    • ACE inhibitors or angiotensin receptor blockers: lisinopril 10 to 40 mg/day PO or equivalent or valsartan 80 to 160 mg PO BID have been associated with improved outcomes in observational cohorts (4)[B].

Second Line
Short-term anticoagulation should be considered in patients with severely reduced LV function to prevent LV thrombus formation. Unfractionated heparin 80 U/kg IV bolus followed by 18 U/kg/hr IV or Lovenox 1 mg/kg SC BID. ‚  

ISSUES FOR REFERRAL


All patients with TSC generally should be comanaged with cardiology while inpatient and referred to cardiology as an outpatient. ‚  

ADDITIONAL THERAPIES


  • Urgent cardiology consultation and consideration of cardiac catheterization
  • Hypotension may require the following:
    • Vasopressors (e.g., dopamine or Levophed) if there is no LV outflow tract gradient (9)[C]
    • Phenylephrine and IV fluids to increase afterload in the presence of an LV outflow tract gradient (9)[C]
    • Cardiogenic shock that is not due to an LV outflow tract gradient may require placement of an intra-aortic balloon pump.

INPATIENT CONSIDERATIONS


Admission Criteria/Initial Stabilization
  • 12-lead ECG
  • Chest radiograph
  • Laboratory testing
  • Echocardiography
  • Patients with TSC usually are admitted for observation because the differential diagnosis includes ACS.

IV Fluids
Normal saline infusion to support BP, if necessary, and no evidence of heart failure ‚  
Discharge Criteria
Generally considered after exclusion of ACS and resolution of ‚  
  • Congestive state
  • Hypotension
  • Profound impairments of systolic function

ONGOING CARE


FOLLOW-UP RECOMMENDATIONS


  • Impairments in systolic function typically resolve in 2 to 3 days but may last as long as 1 month.
  • Patients should follow up with cardiology and serial echocardiography to document improved LV function.

PROGNOSIS


  • Prognosis is excellent. Inpatient mortality is rare and ranges from 0% to 8%.
  • Recurrence is rare; it also has been reported in 0 " “8% of patients.

REFERENCES


11 Bybee ‚  KA, Prasad ‚  A. Stress-related cardiomyopathy syndromes. Circulation.  2008;118(4):397 " “409.22 Dote ‚  K, Sato ‚  H, Tateishi ‚  H, et al. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases [in Japanese]. J Cardiol.  1991;21(2):203 " “214.33 Fitzgibbons ‚  TP, Madias ‚  C, Seth ‚  A, et al. Prevalence and clinical characteristics of right ventricular dysfunction in transient stress cardiomyopathy. Am J Cardiol.  2009;104(1):133 " “136.44 Templin ‚  C, Ghadri ‚  JR, Diekmann ‚  J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med.  2015; 373(10): 929 " “935.55 Paur ‚  H, Wright ‚  PT, Sikkel ‚  MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a Ž ²2-adrenergic receptor/Gi-dependent manner: a new model of takotsubo cardiomyopathy. Circulation.  2012;126(6): 697 " “706.66 Madias ‚  C, Fitzgibbons ‚  TP, Alsheikh-Ali ‚  AA, et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm.  2011;8(4):555 " “561.77 Randhawa ‚  MS, Dhillon ‚  AS, Taylor ‚  HC, et al. Diagnostic utility of cardiac biomarkers in discriminating takotsubo cardiomyopathy from acute myocardial infarction. J Card Fail.  2014;20(1):2 " “8.88 Medeiros ‚  K, O 'Connor ‚  MJ, Baicu ‚  CF, et al. Systolic and diastolic mechanics in stress cardiomyopathy. Circulation.  2014;129(16):1659 " “1667.99 Hunt ‚  SA, Abraham ‚  WT, Chin ‚  MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol.  2009;53(15):e1 " “e90.

SEE ALSO


Algorithm: Chest Pain/Acute Coronary Syndrome ‚  

CODES


ICD10


I51.81 Takotsubo syndrome ‚  

ICD9


429.83 Takotsubo syndrome ‚  

SNOMED


441541008 Takotsubo cardiomyopathy ‚  

CLINICAL PEARLS


  • TSC is a cause of reversible LV dysfunction with a clinical presentation indistinguishable from the ACS, particularly ST-segment elevation MI.
  • Echocardiography may strongly suggest the diagnosis.
  • Treatment is supportive and should include diuretics and ACE inhibitors in patients with CHF.
Copyright © 2016 - 2017
Doctor123.org | Disclaimer